Incannex Healthcare Past Earnings Performance
Past criteria checks 0/6
Incannex Healthcare's earnings have been declining at an average annual rate of -14.7%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been declining at an average rate of 4.8% per year.
Key information
-14.7%
Earnings growth rate
-59.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | -4.8% |
| Return on equity | -351.1% |
| Net Margin | -26,922.1% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Incannex Healthcare makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -23 | 18 | 5 |
| 30 Jun 24 | 0 | -18 | 17 | 1 |
| 31 Mar 24 | 1 | 20 | 12 | 3 |
| 31 Dec 23 | 1 | 21 | 10 | 3 |
| 30 Sep 23 | 1 | 5 | 8 | 4 |
| 30 Jun 23 | 0 | -49 | 8 | 6 |
| 31 Mar 23 | 0 | -48 | 7 | 5 |
| 31 Dec 22 | 1 | -48 | 7 | 4 |
| 30 Sep 22 | 1 | -28 | 5 | 4 |
| 30 Jun 22 | 1 | -10 | 5 | 4 |
| 31 Mar 22 | 1 | -10 | 5 | 4 |
| 31 Dec 21 | 1 | -9 | 4 | 4 |
| 30 Sep 21 | 1 | -9 | 5 | 4 |
| 30 Jun 21 | 1 | -9 | 5 | 4 |
| 31 Dec 20 | 1 | -4 | 2 | 3 |
| 30 Sep 20 | 1 | -3 | 2 | 2 |
| 30 Jun 20 | 0 | -3 | 1 | 1 |
| 31 Dec 19 | 0 | -1 | 0 | 1 |
| 30 Sep 19 | 0 | -1 | 0 | 1 |
| 30 Jun 19 | 0 | -1 | 0 | 1 |
| 31 Mar 19 | 1 | -2 | 2 | 0 |
| 31 Dec 18 | 1 | -2 | 2 | 0 |
| 30 Sep 18 | 1 | -2 | 3 | 0 |
| 30 Jun 18 | 1 | -2 | 3 | 0 |
| 31 Mar 18 | 1 | -2 | 2 | 0 |
| 31 Dec 17 | 0 | -2 | 2 | 0 |
| 30 Sep 17 | 0 | -9 | 2 | 0 |
| 30 Jun 17 | 0 | -16 | 2 | 0 |
| 31 Mar 17 | 0 | -15 | 1 | 0 |
| 31 Dec 16 | 0 | -14 | 1 | 0 |
| 30 Sep 16 | 0 | -8 | 1 | 0 |
| 30 Jun 16 | 0 | -1 | 1 | 0 |
Quality Earnings: IXHL is currently unprofitable.
Growing Profit Margin: IXHL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IXHL is unprofitable, and losses have increased over the past 5 years at a rate of 14.7% per year.
Accelerating Growth: Unable to compare IXHL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IXHL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: IXHL has a negative Return on Equity (-351.07%), as it is currently unprofitable.